Lyvema+

Lyvema+ has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €27,725 and a net result of €1,624. Equity remains stable across the filed financial years (±0.9% per year). Its solvency ranks better than 16% of 4,093 sector peers (NACE 69, financial year 2025). The computed 12-month bankruptcy probability is 1.2% (low).